REVIEWS

Y. Sheytanov and I. Sheytanov. RANK/RANK LIGAND/OSTEOPROTEGERIN SYSTEM – PROGRESS IN BONE BIOLOGY RESEARCH. DENOSUMAB – A NEW POSSIBILITY FOR TREATMENT OF OSTEOPOROSIS

Summary. In the last 15 years, a considerable progress in the research of bone biology has been made. There was identified and clarified the RANK/RANK Ligand/OPG pathogenetic pathway. The balance RANK Ligand/OPG turned to be decisive for osteoclast differentiation, activation and survival. It plays a crucial role in the pathogenesis of osteoporosis and some other bone diseases characterized by increased bone resorption. The inhibition of RANK-Ligand is a new therapeutic strategy in this kind of bone pathology. It can be accomplished with antibodies against RANK-Ligand, blockade with synthetic OPG or blockade of post-receptor signals. Lately, there was elaborated a fully-human monoclonal antibody targeting the RAN- Ligand – denosumab with trade name Prolia. In experimental models and in some clinical studies, Prolia inhibits bone resorption and considerably increases bone mineral density. Impressive results were achieved in the 3-year study FREEDOM in postmenopausal women: reduction of the risk of new vertebral fractures by 68%, of hip fractures – by 40%, and of other extrvertebral fractures – by 20%. Denosumab presents a new therapeutic alternative for osteoporosis and for prevention of associated fractures as well.

Key words: RANK, RANK-Ligand, osteoprotegerin, denosumab

ORIGINAL ARTICLES

L. Miteva, I. Manolova, M. Ivanova, R. Stoilov, R. Rashkov and S. Stanilova. LACK OF ASSOCIATION BETWEEN PROMOTER POLYMORPHISM −1082A/G IN INTERLEUKIN-10 GENE AND GENETIC PREDISPOSITION TO SYSTEMIC LUPUS ERYTHEMATOSUS

Summary. The aim of this study was to establish the association between −1082A/G polymorphism of IL10 gene and susceptibility to SLE in individuals from Bulgaria. A total of 157 patients who fulfilled the 1982 revised criteria of the American Rheumatism Association for the diagnosis of SLE were studied. Patients were compared with 126 healthy controls. Genotyping for −1082A/G polymorphism in IL10 gene was performed by amplification refractory mutation system (ARMS) – PCR assay. The distribution and the frequencies of the −1082A/G genotypes among the SLE patients were the following: 56 (0.36) AA, 74 (0.47) AG and 27 (0.27) GG. In the control group, 44 (0.35) were homozygous for the wild A-allele, 65 (0.52) were heterozygous, and the rest of 17 (0.13) were homozygous for the variant G-allele. The genotype GG was more frequent in SLE patients (27% vs 13%), although the difference did not reach statistical significance (p = 0.393). In addition, no association was found between the investigated polymorphism and the clinical manifestations of SLE. In conclusion, our current results suggest that promoter polymorphism −1082A/G in IL10 gene could not play an important role in the susceptibility to SLE in the Bulgarian patients.

Key words: interleukin-10, −1082A/G polymorphism, SLE

I. Gruev and A. Toncheva. CHRONIC RHEUMATIC INFLAMMATION AND SUBCLINICAL ATHEROSCLEROSIS – THE DIFFERENT FACE OF THE PATIENT AT RISK

Summary. The patients with inflammatory rheumatic diseases (IRD) have chronic autoimmune inflammation and high cardiovascular morbidity and mortality, due to accelerated atherosclerosis. The measurement of IMT is a non-invasive method for detection of subclinical atherosclerosis. Several clinical studies have shown that the patients with IRD have significantly higher values of IMT, compared with healthy controls. The aim of our study was to investigate the role of the chronic inflammation for the development of subclinical atherosclerosis in patients with IRD (rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis), in order to demonstrate the increased cardiovascular risk in this specific group of patients. 105 IRD patients and 72 hypertensive patients with one or more additional risk factor were investigated. Assessment of the traditional risk factors for atherosclerosis and markers of inflammation (SR, CRP) and bilateral carotid sonography were done to all patients. For the IRD group, additionally an X-ray and assessment of the number of the affected joints were performed. The IRD patients had better traditional risk profile and higher markers of inflammation, compared to the hypertensive group. They also had thicker intima-media (0.98 mm vs 0.84 mm) and more plaques (27.6% vs 22.2%) compared to sex- and age-matched hypertensive controls. Age and presence of IRD appeared to be independent predictors of subclinical atherosclerosis. In the IRD group, the subclinical atherosclerosis correlated with the duration of
the disease, number of affected joints, age and serum uric acid. Despite of their better traditional risk profile, and on the background of the higher markers of inflammation, the IRD-patients have more apparent signs of subclinical atherosclerosis. The traditional risk calculators should be adapted for this specific group of patients.

**Key words:** inflammatory rheumatic diseases, atherosclerosis, intima-media thickness

**CONTENTS**

**SECOND NATIONAL CONFERENCE ON OSTEOPOROSIS AND OSTEOARTHRITIS**

**PLENARY REPORTS**

A. Batalov, R. Nestorova, Y. Sheytanov, Ts. Petranova and S. Monov. Arthrosenography and degenerative joint diseases ................................................................. 9

M. Boyanov. Dual-energy X-ray absorptiometry: Beyond measuring bone mineral density .................................................. 9

K. Ikononova and A. Toncheva. Osteoimmunology – a new field in bone biology .................................................. 10


Zl. Kolarov and R. Nestorova. Osteoarthrosis and cartilago quality: Achievements, new technologies, newly arisen questions and unsolved problems .................................................. 11

Zl. Kolarov and R. Nestorova. Osteoporosis and bone quality: Achievements, new technologies, newly arisen questions and unsolved problems .................................................. 11

St. Kuzmanova and P. Solakov. Reasons for lack of succession and adherence to treatment with bisphosphonates in women with postmenopausal osteoporosis .................................................. 12


M. Panchovska-Mocheva. Fibromyalgia and overlap with chronic pain syndromes .................................................. 14

Ts. Petranova, R. Rashkov, I. Sheytanov, R. Nestorova, A. Batalov and S. Monov. Ultrasound diagnostics of crystal arthropathies ........................................................................................................ 14

Pl. Popivanov. Bone remodeling and calcium-phosphorus metabolism .................................................................................. 15

V. Raskhova and R. Rashkov. Treatment of degenerative processes of the intervertebral disc – myth or reality .................................................................................................................. 15

R. Stoilov and M. Ivanova. Arthritic disease – a challenge to contemporary medicine .................................................. 15

R. Stoilov and M. Ivanova. Treatment of arthritic disease with chondroprotectors .................................................................................................................. 16


A. Shinkov. Thyroid gland and bone, or a story about the long arm of the hormones .................................................. 17


M. H. Hossain, N. Islam and S. A. Haq. Development of a bengali version of Western Ontario McMaster universities osteoarthritis index (WOMAC) .................................................................................................................. 18

**SCIENTIFIC ANNOUNCEMENTS**


A. Batalov, I. Goranov, R. Nestorova, N. Marinova and K. Garbeva. Chondroprotection in osteoarthritis of knee joint. Results of a 3-month multicenter postmarketing clinical study .................................................................................................................. 19

B. Bonchev, R. Kastelov and P. Temelkov. Direct frontal miniinvasive access to hip endoprosthetics. A 2-year experience .................................................................................................................. 21
R. Grechenlieva. Effects of the use of the preparation Flexodon A in different stages of primary and secondary arthrotic changed joints in the outpatient rheumatologic practice .........................................................21

R. Kastelov, B. Bonchev and N. Vodenicharov. Osteoporotic fractures of the proximal end of the femur: Modern therapeutic options ..............................................................................................................22


V. Peycheva. DONA® – a chondroprotective reflection ..................................................................................................................................................................................................................................................................................23

R. Rashkov, N. Marinova and K. Garbeva. Clinical efficacy and safety of DONA 1500 mg in patients with activated gonarthrosis ..............................................................................................................................................................................................................................23

V. Reshkova and R. Rashkov. Effect of the treatment with epidural applications of methylprednisolone in complications of osteoarthrosis – disc protrusions/herniations ....................................................................................................................................................................................................................................................24

L. Sapundzhiev and S. Lambova. Comparison of the therapeutic effects of lubricants with different molecular weight and local corticosteroids in osteoarthrosis of the hip joint .....................................................................................................................................................................................................................................................24

P. Solakov and St. Kuzmanova. Early unwanted drug effects after Aclasta® ..................................................................................................................................................................................................................................................................................25

R. Stoilov, M. Ivanova, K. Garbeva and N. Marinova. Clinical experience with Ostenil, Ostenil Plus, Veral and Durolane in the treatment of patients with gonarthrosis ..............................................................................................................................................................................................................................................................................................25

P. Todorov and A. Batalov. Facet block in diagnosis and therapy of lumbar osteoarthrosis ............................................26


REVIEWS


ORIGINAL ARTICLES

L. Miteva, I. Manolova, M. Ivanova, R. Stoilov, R. Rashkov and S. Stanilova. Lack of association between promoter polymorphism –1082a/g in interleukin-10 gene and genetic predisposition to systemic lupus erythematosus .....................................................................................................................................................................................................................................................................................................................33

I. Gruev and A. Toncheva. Chronic rheumatic inflammation and subclinical atherosclerosis – the different face of the patient at risk ..............................................................................................................................................................................................................................................................................................39